213 related articles for article (PubMed ID: 36045429)
1. Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment.
Jiang T; Xie L; Zhou S; Liu Y; Huang Y; Mei N; Ma F; Gong J; Gao X; Chen J
J Nanobiotechnology; 2022 Aug; 20(1):394. PubMed ID: 36045429
[TBL] [Abstract][Full Text] [Related]
2. Biguanide-anchored albumin-based nanoplatform inhibits epithelial-mesenchymal transition and reduces the stemness phenotype for metastatic cancer therapy.
Jiang T; Wang J; Xie L; Zhou S; Huang Y; Chen Y; Gao X; Xiao W; Chen J
Acta Biomater; 2023 Nov; 171():565-579. PubMed ID: 37716479
[TBL] [Abstract][Full Text] [Related]
3. Metformin and Docosahexaenoic Acid Hybrid Micelles for Premetastatic Niche Modulation and Tumor Metastasis Suppression.
Jiang T; Chen L; Huang Y; Wang J; Xu M; Zhou S; Gu X; Chen Y; Liang K; Pei Y; Song Q; Liu S; Ma F; Lu H; Gao X; Chen J
Nano Lett; 2019 Jun; 19(6):3548-3562. PubMed ID: 31026397
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma
Xiao Q; Liu H; Wang HS; Cao MT; Meng XJ; Xiang YL; Zhang YQ; Shu F; Zhang QG; Shan H; Jiang GM
Theranostics; 2020; 10(22):10245-10261. PubMed ID: 32929346
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
8. Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.
Tyszka-Czochara M; Lasota M; Majka M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29337896
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model.
Leonel C; Borin TF; de Carvalho Ferreira L; Moschetta MG; Bajgelman MC; Viloria-Petit AM; de Campos Zuccari DA
J Mammary Gland Biol Neoplasia; 2017 Mar; 22(1):27-41. PubMed ID: 28078601
[TBL] [Abstract][Full Text] [Related]
10. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Shen Z; Liao X; Shao Z; Feng M; Yuan J; Wang S; Gan S; Ha Y; He Z; Jie W
BMC Cancer; 2019 Mar; 19(1):262. PubMed ID: 30902084
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
[TBL] [Abstract][Full Text] [Related]
12. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2010 Nov; 9(22):4461-8. PubMed ID: 21088486
[TBL] [Abstract][Full Text] [Related]
13. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
Wang X; Xu J; Wang H; Wu L; Yuan W; Du J; Cai S
Biochem Biophys Res Commun; 2015 Jan; 456(1):320-6. PubMed ID: 25434997
[TBL] [Abstract][Full Text] [Related]
14. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter.
Banerjee P; Surendran H; Chowdhury DR; Prabhakar K; Pal R
J Mol Med (Berl); 2016 Dec; 94(12):1397-1409. PubMed ID: 27534967
[TBL] [Abstract][Full Text] [Related]
15. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
16. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines.
Leonel C; Ferreira LC; Borin TF; Moschetta MG; Freitas GS; Haddad MR; de Camargos Pinto Robles JA; Aparecida Pires de Campos Zuccari D
Anticancer Agents Med Chem; 2017; 17(8):1113-1125. PubMed ID: 28042775
[TBL] [Abstract][Full Text] [Related]
18. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition.
Noguchi S; Eitoku M; Moriya S; Kondo S; Kiyosawa H; Watanabe T; Suganuma N
Lung; 2015 Oct; 193(5):691-700. PubMed ID: 26286207
[TBL] [Abstract][Full Text] [Related]
20. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Sakamoto T; Kobayashi S; Yamada D; Nagano H; Tomokuni A; Tomimaru Y; Noda T; Gotoh K; Asaoka T; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
PLoS One; 2016; 11(1):e0145985. PubMed ID: 26726879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
